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severe regurgitation of an aortic stentless bioprosthesis
(Toronto SPV) using the Edwards SAPIEN THV.
CONCLUSIONS
There is a current worldwide trend toward preferential
use of biological rather than mechanical aortic prostheses
in younger age groups. The expanding applicability of
minimally invasive techniques may augment this trend,
further lowering the recommended age for tissue aortic
valve recipients. The stentless valve design may prove ad-
vantageous in case of subsequent VinV therapy. If this
proves to be true, it could lead to an increased use of stent-
less valves. The role of the transcatheter VinV procedure
as an alternative to conventional redo aortic valve replace-
ment needs to be determined. Clearly, this technique and
platform will play a role in the future, with the parameters
of patient selection and specific surgeon/physician to be
defined.
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Brief Technique Reports‘‘Valve-in-valve’’ implantation in a patient with stentless
bioprosthesis and severe intraprosthetic aortic regurgitation
David Attias, MD, Dominique Himbert, MD, Ulrik Hvass, MD, and Alec Vahanian, MD, PhD, Paris, FranceAn 80-year-old man was admitted to our department for
dyspnea (New York Heart Association class III) and angina
pectoris. His medical history included an aortic valve re-
placement (AVR) for aortic stenosis with a size 25 stentless
bioprosthesis associated with a coronary bypass (left internal
thoracic artery to the left anterior descending coronary artery
and saphenous vein to the right coronary artery) in 1999 and
a myocardial infarction in 2004. In 2008, infective endocar-
ditis owing to Streptococcus gallolyticus was adequately
treated by intravenous amoxicillin over 6 weeks, as well as
gentamicin for 15 days, and currently was complicated by
severe intraprosthetic aortic regurgitation (AR).
On admission, 1 month after complete healing of the en-
docarditis, blood pressure was 142/43 mm Hg, and clinical
signs of severe AR and congestive heart failure were present.
Transthoracic and transesophageal echocardiography (TEE)
From the AP-HP, Bichat-Claude Bernard Hospital, Paris, France.
Received for publication April 30, 2009; accepted for publication May 15, 2009;
available ahead of print July 6, 2009.
Address for reprints: David Attias, MD, AP-HP, Bichat-Claude Bernard Hospital,
Cardiology, 46 rue Henri Huchard, 75018 Paris, France (E-mail: david.attias@
bch.aphp.fr).
J Thorac Cardiovasc Surg 2009;138:1020-2
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2009.05.0071020 The Journal of Thoracic and Cardiovascular Sushowed severe intraprosthetic AR owing to perforation and
prolapse of the posterior cusp (Figure 1, A), left ventricular
dilatation, and preserved left ventricular ejection fraction.
Neither vegetations, abscesses, nor paraprosthetic leaks
were noted. There were no biological signs of ongoing infec-
tion and all blood cultures were negative.
A coronary angiogram showed occlusion of the three
native vessels and a patent left internal thoracic graft, but
occlusion of the saphenous vein–right coronary bypass.
Finally, preoperative computed tomography discovered
a limited pulmonary cancer, indicating surgical lobectomy.
The mortality risk was 26% as predicted by the Euro-
SCORE and 18% according to The Society of Thoracic Sur-
geons Predicted Risk of Mortality. After multidisciplinary
evaluation, transcatheter aortic valve implantation (TAVI)
was considered on a compassionate basis to permit thoracic
surgery. After informed consent, a 29-mm CoreValve Re-
valving System (Medtronic, Inc, Minneapolis, Minn) was
implanted into the stentless bioprosthesis via percutaneous
femoral access using a 10F Prostar XL device (Abbott
Vascular, Inc, Abbott Park, Ill) as the pre-closing device.
The procedure was performed in the catheterization labora-
tory, under general anesthesia, with fluoroscopic and TEE
guidance. Technical aspects of CoreValve Revalving
System implantation have previously been detailed.1rgery c October 2009
Brief Technique ReportsFIGURE 1. Transesophageal echocardiography (TEE) showed severe intraprosthetic AR owing to perforation and prolapse of the posterior cusp (A). Post-
implantation angiogram (B) and TEE (C and D) showed the good positioning of the CoreValve Revalving System with no residual aortic regurgitationIn the present case, the absence of angiographic land-
marks (no calcification on the stentless bioprosthesis) ren-
dered adequate positioning difficult. Positioning was
guided by repeated angiography and TEE monitoring. Im-
mediate postimplantation TEE and angiographic controls
confirmed the correct position of the prosthesis with neither
AR nor coronary obstruction (Figure 1, B, C, and D). The
mean residual transprosthetic gradient was 3 mm Hg. A
computed tomographic scan confirmed the proper position-
ing of the prosthesis (Figure 2). Postimplantation recovery
was uneventful. The patient was discharged on day 12 and
was then able to undergo an early curative pulmonary lobec-
tomy 3 weeks later.
DISCUSSION
Seven years after the first-in-man report, TAVI has
emerged as an alternative therapy for patients with severe
symptomatic aortic stenosis who are considered at high
risk or with contraindications for surgical AVR.1 Short-
term and midterm results are encouraging. However, owingThe Journal of Thoracic and Cto the yet unsolved issue of prosthesis durability, TAVI
should still be restricted to noncandidates for conventional
AVR.
Besides these accepted indications, TAVI may represent
an interesting alternative to AVR in high-risk elderly pa-
tients with a dysfunctioning bioprosthesis needing reopera-
tion, which is associated with higher morbidity and
mortality owing to comorbidities or sternal re-entry with pat-
ent thoracic artery grafts.
The feasibility of transapical valve-in-valve implantation
in mitral or aortic bioprostheses has initially been proven in
the pig model.2 Recently, the first-in-man valve-in-valve
procedure for the treatment of severe AR owing to degener-
ation of a Mitroflow bioprosthesis (Sorin Biomedica Spa,
Saluggio, Italy) has been reported.3
To our knowledge, this is the first description of TAVI for
treatment of severe AR in a malfunctioning stentless bio-
prosthesis. Compared with stented bioprostheses, stentless
bioprostheses may provide some hemodynamic advantages
and a longer durability.4ardiovascular Surgery c Volume 138, Number 4 1021
Feas
tran
Eric D
Que´be
From the
Received
for pub
Address f
Hospita
rodes@
J Thorac
0022-522
Copyrigh
doi:10.10
Brief Technique Reports
1022FIGURE 2. Computed tomographic scan confirmed the good positioning of the CoreValve Revalving System.In our case, AR was actually due to the sequelae of
endocarditis and not to structural valve degeneration. Tech-
nical issues for TAVI in patients with stentless bioprostheses
are different from those in patients with native aortic stenosis
or a stented bioprosthesis. Positioning may be more difficult
because of the absence of calcification, and the role of con-
comitant TEE should be emphasized. The absence of calci-
fication or stents may also theoretically increase the risk of
prosthesis migration because of potentially less stable an-
chorage on the aortic annulus. However, this report illus-
trates the feasibility of TAVI in patients with severe
dysfunction of a stentless bioprosthesis.
Valve-in-valve implantation may represent a promising
opportunity for the future,5 inasmuch as limited durability
is the major concern of stented or stentless bioprostheses.
Further studies including a large number of patients and lon-
ger follow-up are required to define the exact role of TAVI inibility of transapical aortic valv
sesophageal echocardiography
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The Journal of Thoracic and Cardiovascular Suelderly patients with a degenerated bioprosthesis that
requires reintervention.
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Transapical aortic valve implantation (TAVI) is emerging as
an alternative to surgical aortic valve replacement for the
treatment of patients with severe aortic stenosis considered
to be at very high or prohibitive surgical risk.1 In this report
we present, for the first time, a case of TAVI fully guided by
transesophageal echocardiography (TEE), with no angiogra-
phy, and we also discuss the usefulness of echocardiography
for guiding TAVI procedures.
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